List of Tpoxx drug patents
Tpoxx is owned by Siga Technologies.
Tpoxx contains Tecovirimat.
Tpoxx has a total of 9 drug patents out of which 0 drug patents have expired.
Tpoxx was authorised for market use on 18 May, 2022.
Tpoxx is available in solution;intravenous dosage forms.
Tpoxx can be used as tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg, treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.
Drug patent challenges can be filed against Tpoxx from 2022-07-13.
The generics of Tpoxx are possible to be released after 04 September, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8124643 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(1 year, 2 months from now) | |
| US9339466 | SIGA TECHNOLOGIES | Polymorphic forms of ST-246 and methods of preparation |
Mar, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802714 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(1 year, 2 months from now) | |
| US8530509 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(1 year, 2 months from now) | |
| US8039504 | SIGA TECHNOLOGIES | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jul, 2027
(4 years from now) | |
| US9907859 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(8 years from now) | |
| US9233097 | SIGA TECHNOLOGIES | ST-246 liquid formulations |
Aug, 2031
(8 years from now) | |
| US10576165 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(8 years from now) | |
| US7737168 | SIGA TECHNOLOGIES | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Sep, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 13, 2023 |
Drugs and Companies using TECOVIRIMAT ingredient
NCE-1 date: 2022-07-13
Market Authorisation Date: 18 May, 2022
Treatment: Treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg; Tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg
Dosage: SOLUTION;INTRAVENOUS
TPOXX family patents
30
United States
8
China
8
Canada
7
Korea, Republic of
7
Japan
7
Israel
6
Mexico
6
Australia
6
European Union
5
Singapore
3
Argentina
3
Denmark
2
Russia
2
Brazil
2
Peru
2
South Africa
1
Spain
1
New Zealand
1
AP
1
Poland
1
Chile
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic